BRPI0111191B8 - moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos - Google Patents

moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos

Info

Publication number
BRPI0111191B8
BRPI0111191B8 BRPI0111191A BRPI0111191B8 BR PI0111191 B8 BRPI0111191 B8 BR PI0111191B8 BR PI0111191 A BRPI0111191 A BR PI0111191A BR PI0111191 B8 BRPI0111191 B8 BR PI0111191B8
Authority
BR
Brazil
Prior art keywords
mutant molecules
soluble ctla4
production
ctla4
molecules
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
R Naemura Joseph
Bajorath Jurgen
S Linsley Peter
J Peach Robert
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0111191A publication Critical patent/BR0111191A/pt
Publication of BRPI0111191B1 publication Critical patent/BRPI0111191B1/pt
Publication of BRPI0111191B8 publication Critical patent/BRPI0111191B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0111191-4 2000-05-26 2001-05-23 moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos BRPI0111191B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (3)

Publication Number Publication Date
BR0111191A BR0111191A (pt) 2004-07-06
BRPI0111191B1 BRPI0111191B1 (pt) 2019-12-31
BRPI0111191B8 true BRPI0111191B8 (pt) 2021-05-25

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111191-4 BRPI0111191B8 (pt) 2000-05-26 2001-05-23 moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos

Country Status (41)

Country Link
EP (3) EP3029062A1 (Direct)
JP (1) JP4328525B2 (Direct)
KR (2) KR100889887B1 (Direct)
CN (2) CN1309735C (Direct)
AR (1) AR031699A1 (Direct)
AT (1) ATE271066T1 (Direct)
AU (2) AU6346601A (Direct)
BE (1) BE2011C041I2 (Direct)
BR (1) BRPI0111191B8 (Direct)
CA (1) CA2409748C (Direct)
CY (2) CY2011019I1 (Direct)
CZ (1) CZ304451B6 (Direct)
DE (2) DE60104282T2 (Direct)
DK (1) DK1248802T3 (Direct)
EC (1) ECSP024365A (Direct)
EE (2) EE05458B1 (Direct)
EG (1) EG24459A (Direct)
ES (2) ES2225549T3 (Direct)
FR (1) FR11C0053I2 (Direct)
GE (1) GEP20053658B (Direct)
HK (1) HK1048126B (Direct)
HU (2) HU228137B1 (Direct)
IL (1) IL152315A (Direct)
LT (1) LT5133B (Direct)
LU (1) LU91902I2 (Direct)
LV (1) LV12994B (Direct)
MX (1) MXPA02011534A (Direct)
MY (1) MY136113A (Direct)
NO (2) NO330797B1 (Direct)
PE (1) PE20011338A1 (Direct)
PL (1) PL206267B1 (Direct)
PT (1) PT1248802E (Direct)
RU (1) RU2283847C2 (Direct)
SI (1) SI1248802T1 (Direct)
SK (1) SK288131B6 (Direct)
TR (1) TR200402703T4 (Direct)
TW (2) TWI319405B (Direct)
UA (1) UA87432C2 (Direct)
UY (1) UY26723A1 (Direct)
WO (1) WO2001092337A2 (Direct)
ZA (1) ZA200208944B (Direct)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EP1372696B1 (en) * 2000-07-03 2008-07-23 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble ctla4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
PT1397153E (pt) 2001-05-23 2008-06-12 Bristol Myers Squibb Co Métodos para proteger um transplante alogénico de ilhéus utilizando moléculas mutantes de ctla4 solúveis
EP1496931A4 (en) * 2002-04-19 2009-07-01 Bristol Myers Squibb Co METHODS OF TREATING AUTOIMMUNE DISEASE USING SOLUBLE CTLA4 MOLECULE AND ARMM OR NSAID
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
CN101857851A (zh) 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
KR101088223B1 (ko) * 2002-12-23 2011-11-30 브리스톨-마이어스 스큅 컴퍼니 단백질 생산을 위한 포유류 세포 배양 방법에서의 생산물품질 향상
PL378879A1 (pl) 2002-12-30 2006-05-29 Amgen Inc. Terapia skojarzona z czynnikami kostymulującymi
WO2005044188A2 (en) 2003-10-27 2005-05-19 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
DK1969007T3 (da) * 2005-12-20 2013-11-25 Bristol Myers Squibb Co Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
KR101546441B1 (ko) 2006-12-20 2015-08-24 엠엠알글로벌, 인코포레이티드 항체 및 이들의 제조 및 사용 방법
CA2703263C (en) 2007-11-01 2014-03-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
EP2344540B1 (en) * 2008-10-02 2017-11-29 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
MX2013009741A (es) 2011-02-23 2014-01-17 Amgen Inc Medio de cultivo celular para exposicion a uvc y metodos relacionados al mismo.
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
MX385969B (es) * 2012-05-11 2025-03-18 Medimmune Ltd Variantes de antígeno 4 del linfocito t citotóxico (ctla-4).
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
CN104519900A (zh) 2012-06-27 2015-04-15 欧尔本生物科技有限责任公司 用于治疗糖尿病的ctla4融合蛋白
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
BR112016015797B1 (pt) 2014-01-13 2022-10-11 Amgen Inc Método para diminuir o teor de glicoforma de alta manose de uma proteína recombinante e método de produção de uma proteína recombinante
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
FI3926051T3 (fi) 2014-06-04 2024-06-18 Amgen Inc Menetelmiä nisäkässoluviljelmien keräämiseksi
KR102623965B1 (ko) 2014-12-01 2024-01-11 암젠 인크 당단백질의 글리칸 함량 수준을 조작하는 방법
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
WO2016168771A2 (en) 2015-04-17 2016-10-20 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
EP3702470A3 (en) 2015-09-09 2020-10-07 The Trustees of Columbia University in the City of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
CN108350416A (zh) 2015-11-09 2018-07-31 百时美施贵宝公司 操纵在cho细胞中产生的多肽的品质属性的方法
CN109715210B (zh) * 2016-09-19 2023-05-30 昂科医药 Cd80和cd86结合蛋白组合物及其用途
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
MX2019012567A (es) 2017-04-20 2020-02-13 Egenesis Inc Metodos para generar animales geneticamente modificados.
EP4219540A3 (en) 2017-10-10 2023-12-06 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
US12297253B2 (en) 2018-01-03 2025-05-13 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
WO2021038296A2 (en) 2019-08-27 2021-03-04 Tonix Pharma Holdings Limited Modified tff2 polypeptides
NZ781142A (en) 2019-12-06 2023-05-26 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
KR20230008830A (ko) 2020-05-08 2023-01-16 리제너론 파마슈티칼스 인코포레이티드 Vegf 트랩 및 미니-트랩 및 안구 장애 및 암의 치료 방법
KR20230026434A (ko) 2020-06-18 2023-02-24 리제너론 파아마슈티컬스, 인크. 미처리된 c-말단 리신을 정확하게 측정하기 위한 중질 펩티드 접근법
WO2022027013A1 (en) 2020-07-28 2022-02-03 Seagen Inc. Methods and systems for producing polypeptides
JP2025500887A (ja) 2021-12-16 2025-01-15 ブリストル－マイヤーズ スクイブ カンパニー ウイルス不活化用界面活性剤
US20230332201A1 (en) 2022-03-02 2023-10-19 Regeneron Pharmaceuticals, Inc. Cell culture methods for antibody production

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
AU661854B2 (en) * 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
EP1119253A4 (en) * 1998-10-07 2005-12-21 Millennium Pharm Inc NEW SPECIFIC MOLECULES OF Th2 AND USES THEREOF
EP1372696B1 (en) * 2000-07-03 2008-07-23 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble ctla4 molecule

Also Published As

Publication number Publication date
HK1048126A1 (en) 2003-03-21
JP4328525B2 (ja) 2009-09-09
NO20025656D0 (no) 2002-11-25
LT2002114A (en) 2003-12-29
UA87432C2 (uk) 2009-07-27
ATE271066T1 (de) 2004-07-15
GEP20053658B (en) 2005-11-10
FR11C0053I1 (Direct) 2012-01-13
EP1248802B9 (en) 2005-05-11
EE201100050A (et) 2011-10-17
JP2004511213A (ja) 2004-04-15
EP1536234A2 (en) 2005-06-01
UY26723A1 (es) 2001-12-28
EP1248802B1 (en) 2004-07-14
IL152315A0 (en) 2003-05-29
NO330797B1 (no) 2011-07-18
KR100889887B1 (ko) 2009-03-24
LT5133B (lt) 2004-05-25
AU2001263466C1 (en) 2006-10-26
NO2011027I2 (Direct) 2011-12-15
LV12994B (en) 2003-08-20
PL206267B1 (pl) 2010-07-30
WO2001092337A2 (en) 2001-12-06
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
IL152315A (en) 2010-04-15
CY1117625T1 (el) 2017-04-26
EE05458B1 (et) 2011-08-15
EE200200659A (et) 2004-06-15
BRPI0111191B1 (pt) 2019-12-31
KR100895134B1 (ko) 2009-05-04
BR0111191A (pt) 2004-07-06
DK1248802T3 (da) 2004-11-15
AU2001263466B2 (en) 2006-04-27
CN101255192A (zh) 2008-09-03
MY136113A (en) 2008-08-29
EE05557B1 (et) 2012-08-15
NO20025656L (no) 2002-11-25
TWI314933B (en) 2009-09-21
HK1071931A1 (en) 2005-08-05
ECSP024365A (es) 2003-03-31
ES2571852T3 (es) 2016-05-27
PT1248802E (pt) 2004-11-30
SI1248802T1 (en) 2005-02-28
HK1048126B (en) 2005-03-04
ES2225549T3 (es) 2005-03-16
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
HUP0302201A3 (en) 2010-01-28
CN1441810A (zh) 2003-09-10
CA2409748C (en) 2008-09-16
CZ304451B6 (cs) 2014-05-14
DE60104282T2 (de) 2005-10-13
AR031699A1 (es) 2003-10-01
NO2011027I1 (no) 2012-01-09
HUP0302201A2 (hu) 2003-10-28
EP1536234A3 (en) 2009-06-03
SK288131B6 (sk) 2013-10-02
WO2001092337A3 (en) 2002-05-10
DE60104282D1 (de) 2004-08-19
ZA200208944B (en) 2004-02-13
TWI319405B (en) 2010-01-11
SK15702002A3 (sk) 2004-01-08
CN1309735C (zh) 2007-04-11
HU228137B1 (en) 2012-12-28
CY2011019I1 (el) 2016-12-14
CA2409748A1 (en) 2001-12-06
BE2011C041I2 (Direct) 2020-08-20
FR11C0053I2 (fr) 2013-01-11
EP3029062A1 (en) 2016-06-08
PL366231A1 (en) 2005-01-24
RU2283847C2 (ru) 2006-09-20
CZ20023892A3 (cs) 2003-09-17
KR20030009502A (ko) 2003-01-29
MXPA02011534A (es) 2004-08-12
EG24459A (en) 2009-07-16
AU6346601A (en) 2001-12-11
TW200906857A (en) 2009-02-16
TR200402703T4 (tr) 2004-11-22
EP1536234B1 (en) 2016-03-16
HUS1300012I1 (hu) 2016-08-29
PE20011338A1 (es) 2002-01-13
DE122011100063I1 (de) 2012-06-14

Similar Documents

Publication Publication Date Title
BRPI0111191B8 (pt) moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
Mekalanos et al. Enzymic activity of cholera toxin. II. Relationships to proteolytic processing, disulfide bond reduction, and subunit composition.
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
DK1090039T3 (da) Peptidsammensætning som immunogen til behandling af allergi
AR036272A1 (es) Genes de metiltransferasas y usos de los mismos
BR112022026575A2 (pt) Anticorpos de alta afinidade que alvejam tau fosforilado em serina 413
Bierlmeier et al. Sortase‐Mediated Multi‐Fragment Assemblies by Ligation Site Switching
BR9909639A (pt) Processos para reduzir a alergenicidade de uma proteìna não humana e para produzir uma proteìna tendo reduzida alergenicidade, proteìna mutante tendo reduzida alergenicidade, dna, vetor de expressão, células hospedeiras, composição farmacêutica, e, substilisina humana
BR0015287A (pt) Moléculas recombinantes de fusão
AU2003287115A1 (en) Fluorescent proteins from copepoda species and methods for using same
Humphries et al. Expression of the class 1 outer-membrane protein of Neisseria meningitidis in Escherichia coli and purification using a self-cleavable affinity tag
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
MXPA04005992A (es) Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa.
Bian et al. The roles of surface loop insertions and disulfide bond in the stabilization of thermophilic WF146 protease
Albers et al. The sialyl-O-acetylesterase NanS of Tannerella forsythia encompasses two catalytic modules with different regiospecificity for O7 and O9 of sialic acid
WO2002102852A3 (en) Modified cd8 molecule, nucleic acid encoding said molecule, and their therapeut ic use
FR2792651B1 (fr) Sequence genomique et polypeptides de pyrococcus abyssi, leurs fragments et leurs utilisations
Kočevar et al. Improved acylation method enables efficient delivery of functional palmitoylated cystatin into epithelial cells
Morgan et al. Structural and functional characterisation of two proteolytic fragments of the bacterial protein toxin, pneumolysin
Iseki et al. Purification and liposomal reconstitution of the oligopeptide transport activity in rat renal cortex using ceftibuten-affinity chromatography
Váchová et al. Calcium as a regulator of Bacillus megaterium cytoplasmic proteolytic activity in vitro
WO2005040208A3 (en) Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use
TR200401035T2 (tr) Arıtılmış proteinler, rekombinan DNA dizileri ve kahve bitkilerinin olgunlaşmasını kontrol etmek için işlemler
BRPI0409277A (pt) método e composição para a remodelagem, in vitro, de uma molécula de peptìdeo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/12/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/05/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2724 DE 21/03/2023 POR TER SIDO INDEVIDA.